DDRGK1 and spondyloepimetaphyseal dysplasia: For patients suffering from SEMD, the DDRGK1 gene should be the focus as a potential target, and from the perspective of gene treatment, DDRGK1-targeted gene therapy may be used in a novel approach in the future.